33results about How to "Enhanced cellular uptake" patented technology

Compounds, compositions and methods are provided for inhibiting the expression of human mdm2. The compositions include antisense compounds targeted to nucleic acids encoding mdm2. Methods of using these oligonucleotides for inhibition of mdm2 expression and for treatment of diseases such as cancers associated with overexpression of mdm2 are provided.

Novel amine compounds are provided by the present invention. Methods of preparing and using said novel amine compounds are also provided.

The present invention feature antisense IAP oligonucleotides and other negative regulators of the IAP anti-apoptotic pathway, and methods for using them to enhance apoptosis.

Novel amine compounds are provided by the present invention. Methods of preparing and using said novel amine compounds are also provided.

The present invention provides a method for combining the advantages of encoded molecule fragments made by split and mix synthesis with the advantages of template directed synthesis of molecules. The method provided in the invention comprises the steps of: Adding a linker molecule L to one or more reaction wells; Adding a molecule fragment to each of said reaction wells; Adding an oligonucleotide identifier to each of said reaction wells; Subjecting said wells to conditions sufficient to allow said molecule fragments and said oligonucleotie identifiers to become attached to said linker molecule, or conditions sufficient for said molecule fragments to bind to other molecule fragments and sufficient for said oligonucleotide identifiers to bind to other oligonucleotide identifiers; Combining the contents of said one or more reaction wells; Optionally, distributing the combined product to one or more new reaction wells; Optionally, repeating steps b) to e) one or more times; Contacting the resulting bifunctional molecule(s) of step e) or g) with one or more Contacting the resulting bifunctional molecule(s) of step e) or g) with one or more (oligonucleotide) templates each capable of hybridizing to at least one of the oligonucleotide identifiers added in step c).

The invention provides a PLGA (polylactic acid-hydroxyacetic acid) nano-drug carrier which is composed of PLGA nano microsphere kernel and an anillic aldehyde crosslinked chitosan housing. A preparation method of the polylactic acid-hydroxyacetic acid copolymer nano-drug carrier is as follows: dispersing a PLGA organic phase which takes dichloromethane and alcohol as a mixed solvent in a water phase to prepare PLGA microspheres by taking PVA (polyvinyl acetate) as an emulsifier by virtue of an one-off emulsion process; then, adding the PLGA microspheres into chitosan liquor, so that the chitosan is adsorbed on the surfaces of the PLGA microspheres, and then adding the chitosan on the surfaces of anillic aldehyde crosslinked PLGA microspheres. The product has a certain pH environmental responsiveness, can realize controlled release of the drug according to in-vivo pH environmental changes, is high in stability, strong in up-taking capacity for microsphere-coated medicaments by the cells, and has very good application prospect in the drug carrier for treating tumors.

The present invention is drawn to the nucleic and amino acid sequences encoding vaginolysin (VLY) toxin from Gardnerella vaginalis, and biologically active fragments and variants thereof. The invention is also directed to anti-VLY antibodies and to their use therapeutically and in a new ELISA assay of VLY toxin. Other embodiments of the invention are directed to VLY toxoids and to vaccines that use the new VLY toxoids as immunogens.

Disclosed are diagnostic and prognostic kits for the detection and treatment of proliferative diseases such as ovarian cancer, breast cancer, and lymphoma. Also disclosed are cancer therapeutics utilizing IAP antisense nucleic acids IAP fragments, and antibodies which specifically bind IAP polypeptides.

An oligo-guanidine as cell penetrating agents / carriers includes a heterocyclic ring including 4-aminopiperidine, piperazine, morpholine having at least one N-terminal based heterocyclic ring or at least one O-heteroatom based heterocyclic ring tailored with hydrophobic and / or lipophilic group. The oligo-guanidine is adapted as an effective molecular transporter to transport and / or delivery therapeutics, therapeutic candidates, probes, or other molecules of interest across biological barriers including oligonucleotides. Advantageously, the oligo-guanidine is capable of being internalized into cells (in-vitro and in-vivo) with enhanced cellular uptake in nanomolar concentration.

The invention features methods of identifying candidate therapeutic compounds for the treatment of proliferative disorder. The invention also features methods for treating a proliferative disorder.